Understand how tentative approval works in the US generic drug market. Learn about patent litigation, Paragraph IV certifications, and strategic steps to ensure timely market entry.
Explore the legal battle between 180-day generic exclusivity and authorized generics. Learn how the Hatch-Waxman Act works and the strategies used to protect profits.
Landmark court decisions in generic patent law are shaping drug prices, access, and innovation. From Amgen v. Sanofi to Allergan v. Teva, these rulings determine when generics can enter the market-and how much patients pay.
The FDA authorizes generic drugs through the Hatch-Waxman Act and ANDA pathway, ensuring they match brand-name drugs in safety, strength, and effectiveness - while costing up to 85% less. Over 90% of U.S. prescriptions are for generics.